A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The study consists of a Pilot Phase (to assess safety and the local tolerability of highest
AOP LDLA202 dose versus placebo) and a Main Treatment Phase (to compare PK, PD and safety and
tolerability of AOP LDLA202, ONO LDL50 and esmolol bolus administrations by measurement of
blood concentrations of landiolol, esmolol and their metabolites, and by monitoring ECG,
blood pressure and adverse events).